Neuronetics Q3 Net Loss Narrows To $1.7 Mln As Revenue Rises 12.5%; Stock Up
Neuronetics (STIM) reported a narrower Q3 net loss of $1.7M, down from $9.0M YoY, as revenue rose 12.5% to $42.0M. Greenbrook clinic revenue increased 20.1%. Gross margin improved to 52.2%, and operating expenses declined 13%. The company reaffirmed its 2026 revenue guidance of $160M-$164M and raised its gross margin outlook.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise likely attract momentum traders and long-term investors.
Market read
First earnings release for Q3 2026, material for the stock and sector.
What to watch
Potential reimbursement risk and competition from emerging neuromodulation technologies.
Background
Neuronetics reported Q3 2026 results, narrowing loss and raising margin guidance, with stock up 19% post-release.
Ticker impact
Q3 net loss narrowed to $1.7M and revenue rose 12.5% to $42M, with guidance reaffirmed, driving a 19% stock rise.
upward pressure as investors price in better margins and lower expenses
First report of earnings beat and margin expansion; market already reacted with a 19% jump.
Market effects
Improves outlook for mental health device sector and TMS therapy providers.
Positive for US biotech and medtech stocks.
Limited to niche mental health treatment market.
Counterpoint
The narrow loss may mask underlying cash burn; watch for future expense pressures.
Key entities
- companyNeuronetics, Inc.
Medical device company providing TMS therapy.
